AstraZeneca drops COPD drug
Executive Summary
AstraZeneca has halted development of the dual dopamine/beta-2 agonist Viozan after Phase III trials in chronic obstructive pulmonary disease failed to demonstrate "longer term benefits...in comparison with other available therapies"